製品名:4-Chloro-6,7-dimethoxyquinazoline

IUPAC Name:4-chloro-6,7-dimethoxyquinazoline

CAS番号:13790-39-1
分子式:C10H9ClN2O2
純度:98%
カタログ番号:CM121387
分子量:224.64

包装単位 有効在庫 価格(USD) 数量
CM121387-25g in stock ɐƤ
CM121387-100g in stock ȷɐȌ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:13790-39-1
分子式:C10H9ClN2O2
融点:-
SMILESコード:COC1=CC2=NC=NC(Cl)=C2C=C1OC
密度:
カタログ番号:CM121387
分子量:224.64
沸点:345.5°C at 760 mmHg
MDL番号:MFCD01570172
保管方法:Keep in inert atmosphere, store at 2-8°C.

Category Infos

Quinazolines
Quinazolines belong to heterocyclic chemistry, also known as 1,3-naphthalenes. The backbone consists of two six-membered aromatic rings fused to each other, with two nitrogen atoms at positions 1 and 3 on the backbone. The presence of these two nitrogen atoms in quinazoline increases its importance in pharmaceutical and biological reactions. Quinazolines and their derivatives are among the most important heterocyclic compounds due to their diverse chemical reactivity and important range of biological activities.

Column Infos

Fruquintinib
November 08, 2023, FDA has approved FRUZAQLA(fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
FRUZAQLA is the first and only selective inhibitor of all three VEGF receptor kinases approved in the U.S. for previously treated mCRC regardless of biomarker status.

Related Products